Cuvrior - (300 mg; Tablet)

Generic Name	Trientine Tetrahydrochloride	**Innovator**	Orphalan SA
Dosage	300 mg; Tablet	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.